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Abstract
Background: Fibromyalgia (FM) is a chronic, debilitating pain disorder. Dissatisfaction with conventional medicine can
lead people with FM to turn to complementary and alternative medicine (CAM). Two previous overviews of systematic
reviews of CAM for FM have been published, but they did not assessed for risk of bias in the review process.
Methods: Five databases Medline, Embase, AMED (via OVID), Web of Science and Central were searched from their
inception to December 2015. Reference lists were hand-searched. We had two aims: the first was to provide an up-to-
date and rigorously conducted synthesis of systematic reviews of CAM literature on FM; the second was to evaluate
the quality of the available systematic review evidence using two different tools: AMSTAR (Shea et al. BMC Med Res
Methodol 15; 7:10, 2007) and a more recently developed tool ROBIS (Whiting et al. J Clin Epidemiol 69:225-34, 2016)
specifically designed to assess risk of bias in systematic reviews. Any review that assessed one of eight CAM therapies
for participants diagnosed with FM was considered. The individual studies had to be randomised controlled trials
where the intervention was compared to placebo, treatment as usual or waitlist controls to be included. The primary
outcome measure was pain, and the secondary outcome measure was adverse events.
Results: We identified 15 reviews that met inclusion criteria. There was low-quality evidence that acupuncture
improves pain compared to no treatment or standard treatment, but good evidence that it is no better than sham
acupuncture. The evidence for homoeopathy, spinal manipulation and herbal medicine was limited.
Conclusions: Overall, five reviews scored 6 or above using the AMSTAR scale and the inter-rater agreement was good
(83.6%), whereas seven reviews achieved a low risk of bias rating using ROBIS and the inter-rater agreement was fair
(60.0%). No firm conclusions were drawn for efficacy of either spinal manipulation or homoeopathy for FM. There is
limited evidence for topical Capsicum, but further research is required. There is some evidence to support the
effectiveness of acupuncture for FM, but further high-quality trials are needed to investigate its benefits, harms and
mechanisms of action, compared with no or standard treatment.
Systematic review registration: PROSPERO CRD42016035846.
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Background
Description of the condition
Fibromyalgia (FM) is a chronic pain disorder charac-
terised by widespread pain [1]. It has been described as a
‘central sensitization syndrome’ caused by biological ab-
normalities in the central nervous system [2] and is
often associated with other conditions such as irritable
bowel syndrome and depression.
The recently revised FM diagnostic criteria (2011), ap-
proved by the American College of Rheumatology (ACR),
use a FM Symptom Scale by combining the Widespread
Pain Index (WPI) and Symptom Severity Scale (SS)
(Wolfe et al. 2011 [3]). The WPI assesses 19 general body
areas for pain occurring in the preceding 2 weeks. The se-
verity of the person’s fatigue, unrefreshed waking, cogni-
tive symptoms and general somatic symptoms are rated
by the SS for a score ranging from 0 to 12 [3].
FM is reported to affect between 1 and 4% of the
population [4]. The use of the new criteria has reduced
the gender ratio form 7:1 to 2:1 female to male ratio,
which is similar to other chronic pain conditions [5].
FM can develop at any age, including childhood, and
there does not appear to be any variation in prevalence
with regard to country, culture or ethnic group. Surpris-
ingly, there does not appear to be any variation in indus-
trialised/non-industrialised countries [6].
Conventional treatments
Medication is currently the main form of treatment;
there is strong evidence of an effect for several drugs like
antidepressants (e.g. amitriptyline) and muscle relaxants
(e.g. cyclobenzaprine) [7, 8]. However, adverse effects of
medication are frequently experienced [9–12]. FM is dif-
ficult to treat within primary care, and people with FM
often turn to complementary and alternative medicine
(CAM) therapies; therefore, it is a condition that has re-
ceived much attention from CAM researchers [13]. Prior
research has found that around 90% of people with FM
have used at least one form of CAM to manage their
symptoms [14–17].
Description of the interventions
CAM has been defined as ‘…diagnosis, treatment and/or
prevention which complements mainstream medicine by
contributing to a common whole, by satisfying a demand
not met by orthodoxy or by diversifying the conceptual
frameworks of medicine’ (Ernst et al.) ([18], p. 506). This re-
view focuses on eight common CAMs which have featured
in several CAM surveys [19–21]: acupuncture, hypnother-
apy, homoeopathy, osteopathy, chiropractic, herbal medi-
cine, reflexology and aromatherapy (see Appendix 1 for
further details on each therapy).
Why it is important to do this overview
There are two main aims within this overview. The first
is to update the synthesis of reviews of CAM literature
on FM and establish what evidence is currently available
with regard to the efficacy of several CAM practices
used in its treatment. As systematic reviews (SR) are
often considered the least biased source of evidence to
evaluate the efficacy of a particular intervention, this
overview will focus on SRs for FM.
The second aim is to provide a robust assessment of
the evidence in this area using two complementary qual-
ity assessment tools: AMSTAR [22] and ROBIS [23].
Previous overviews of reviews
Taking a look at previous overviews from the last 5 years,
in 2012, Terry et al.’s [1] overview of reviews of CAM
for FM identified five systematic reviews. The reviews
found some evidence of beneficial effects for acupunc-
ture, homoeopathy, hydrotherapy and massage, whilst
no evidence for therapeutic effects for chiropractic treat-
ment of FM symptoms. However, no quality assessment
of the individual reviews was performed.
In 2015, Launche et al. [24] also published a synthesis of
CAM for FM reviews. The AMSTAR scale [22] was used
to assess the quality of the review. In contrast to our over-
view, Lauche et al. [24] did not restrict the type of CAM,
whereas we restricted to the most common CAMs. In
addition, we wanted to apply a more rigorous risk of bias
assessment to the systematic reviews identified; AMSTAR
focuses on the methodological quality of the reviews rather
than risk of bias, so we wanted to compensate for that.
In our overview, all eligible systematic reviews of FM
were assessed using both the AMSTAR scale [22] and
the ROBIS tool [23]. This will provide an up-to-date and
rigorous overview of evidence of CAM for FM.
Methods
This systematic overview was conducted following a pre-
determined written protocol registered on the PROS-
PERO database: registration number, CRD42016035846.
To be considered eligible for this overview, reviews were
required to meet the following criteria:
Type of reviews—all systematic reviews of randomised
controlled trials (RCTs) were included. Quasi-experimental
studies were included only if they were assessed alongside
RCTs and were in the minority. Systematic reviews of
quasi-experimental studies are at higher risk of bias due to
lack of random assignment, but we did not want to exclude
reviews if the majority of included studies were RCTs. All
systematic reviews were included with or without a meta-
analysis. The reviews must have searched more than one
database and reviewed at least one included CAM treat-
ment for FM. However, reviews that assessed several CAM
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in the same review were considered if they included at least
two of the eight relevant CAMS.
Type of participant—reviews that included RCTs using
human subjects diagnosed with FM using standard
diagnostic criteria (e.g. ACR criteria) were eligible. No
restrictions regarding age, gender, condition duration
or intensity were applied.
Type of intervention—reviews of effects of any of the
following eight CAM therapies were included:
acupuncture, hypnotherapy, homoeopathy, osteopathy,
chiropractic, herbal medicine, reflexology and
aromatherapy. Reviews that included multiple CAM
therapies were also included, as long as the CAM
therapies were not used in combination. Reviews of
complex systems of combinations of a range of
therapeutic modalities such as Traditional Chinese
medicine (TCM) were excluded as it would be too
difficult to establish the separate effects of the individual
aspects of this combined approach.
Reviews that only assessed CAM therapies used as an
adjunct therapy to conventional medicine were
excluded. CAMs that were used in conjunction with
other interventions frequently recommended by
mainstream healthcare practitioners to treat FM
(exercise, patient education, cognitive/behavioural
therapies and hydrotherapy) were also excluded. If
reviews had also included some trials using additional
medication/exercise, these were included, but those
particular trials were excluded from the analysis (both
narrative and meta-analysis).
Type of comparator—placebo, no treatment, treatment-
as-usual or waitlist control groups were permissible as
the comparator.
Type of outcome—any review that included studies that
reported validated measures of pain (e.g. tender point
count on palpation, pain intensity, or assessed using a
standardised pain measure such as a visual analogue
scale (VAS), McGill Pain Questionnaire (MPQ) [25]
and Chronic Pain Grade Scale [26]). Other outcomes
extracted were adverse events.
Excluded reviews: Any reviews that included participants
with co-morbidities (e.g. cancer, drug addiction) were ex-
cluded. See Table 4 in Appendix 2 for excluded reviews.
The following databases were searched from their in-
ception to December 2015: Medline, Embase and AMED
(via Ovid), Web of Science and Central via Cochrane li-
brary, using a combination of MeSH and key word terms
(see Appendix 3 for the search strategy). Conference ab-
stracts/protocols were searched using Web of Science,
and authors were contacted to establish progress of their
work (see Table 5 in Appendix 2). Reviews had to be
published to be included. All titles and abstracts re-
trieved from the search were assessed for eligibility
against the predetermined inclusion criteria by two
reviewers (RP, VL). Any review appearing to meet the
inclusion criteria based on the abstract was retrieved as
a full document. The full-text articles were read in their
entirety to assess eligibility by two reviewers (RP, VL)
and decisions on inclusion and exclusion recorded (see
Fig. 1 for flow diagram). Any disagreements were dis-
cussed with a third author (RC). Excluded reviews were
recorded alongside reasons (see Table 4 in Appendix 2).
Reference lists of all full-text articles were hand-
searched for additional studies. We only included Eng-
lish language papers as we did not have access to the
translation skills of someone trained in using the ROBIS
tool to be able to cross-check the ROBIS tool effectively.
Authors of any abstracts/protocols were contacted to es-
tablish the status of review.
Data extracted
Two reviewers (RP, VL) independently extracted data and
summarised the review in a characteristic table (see Table 1).
Data was extracted from full-text reviews using a standar-
dised data extraction form. The extraction form was piloted
prior to starting the overview and refined. Disagreements
were resolved through discussion with a third reviewer
(RC). Information was extracted from each included review
on author, date of review, country, list of studies included
in the individual review, intervention and comparator sum-
mary, number of participants, diagnosis criteria, meta-
analysis results or summary of main between-group results,
whether a sensitivity or subgroup analysis was conducted,
risk of bias assessment and adverse events.
We extracted the mean and standard deviation (SD) of
continuous variables and any between-group statistical ana-
lyses. We reported the standard mean difference (SMD)
and 95% confidence intervals (CI) and results of any tests
of heterogeneity reported in the relevant meta-analyses. If
‘pain’ was measured alongside another outcome (e.g. dis-
comfort) and recorded as a single variable, we would ex-
tract the data and highlight this in the table and text.
Data synthesis
Due to the expected overlap of studies and heterogeneity
between reviews (particularly with regard to interven-
tions and comparator arms), we conducted a narrative
synthesis of the findings rather than pooling of meta-
analyses from the included reviews.
Assessment of methodological quality/bias of the included
reviews
The quality of each systematic review was assessed using
both the frequently used and validated AMSTAR tool
[22, 27] alongside the newly developed ROBIS tool [23].
AMSTAR is an 11-item tool that has been used fre-
quently to check the quality of a systematic review and
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determine whether the most important elements are
reported (http://www.robis-tool.info). It consists of a
series of questions with four possible answers. Each
question is not evenly weighted so and although an
overall score is sometimes reported, this is not what
the tool is intended for. It is frequently used in
Cochrane overviews and by the Scottish Intercollegi-
ate Guidelines Network (SIGN). It is intended for re-
views that address questions of effectiveness that
include just randomised controlled trials (RCTs).
However, AMSTAR does not cover some quality
items, and each item is not weighted the same; thus,
we felt it important to also use the newly developed
ROBIS tool.
The aim of the ROBIS tool is to evaluate the level of
bias present within a systematic review (http://
amstar.ca/About_Amstar.php). This tool assesses the
level of bias across four domains: study eligibility cri-
teria, identification and selection of studies, data collec-
tion and study appraisal and synthesis and findings.
Each domain has signalling questions and a judgment
of concerns about risk of bias of the domain (low,
high or unclear—see Table 6 in Appendix 4). In the
final phase, the reviewer makes a judgment about the
overall risk of bias. In contrast to AMSTAR, ROBIS
has a wider application and is intended for assessing
effectiveness, diagnostic test accuracy, prognosis and
aetiology. It has an optional phase to assess the ap-
plicability of the review to the research question of
interest.
Two reviewers (RP, VL) independently assessed each re-
view using both tools. Both reviewers had limited experi-
ence of using the ROBIS tool, so a third reviewer who
helped develop the tool (PD) was asked to also complete
the ratings. Meta-analyses were checked by a statistician
experienced in meta-analyses (CP). The inter-rater reli-
ability of overall ratings using each instrument (AMSTAR
and ROBIS) was calculated also using the unweighted
kappa statistic and percentage agreement. We interpreted
cut-offs for Kappa values as <0.20 = poor agreement, 0.21
to 0.40 = fair, 0.41 to 0.60 = moderate, 0.61 to 0.80 = good
and 0.81 to 1.00 = very good agreement.
Deviation from the protocol
In our protocol [PROSPERO CRD42016035846], we said
we would not apply any language restrictions; however,
it was decided that we would only include English lan-
guage papers as the ROBIS tool would be a complex tool
to ask someone to extract data with.
Fig. 1 Flow diagram
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Results
Results of the literature search
The search strategy yielded 568 potentially relevant papers
for inclusion. After 125 duplicate titles were removed, 443
remained. Once screened, 98 papers were identified as po-
tentially eligible and full-text copies were retrieved and
reviewed by the two reviewers (RP, VL) (see Fig. 1 for flow
diagram). From these papers, 15 were included in this over-
view, and the reasons for excluding articles are presented in
Table 4 in Appendix 2. Results of the included studies are
presented in Table 1. The summarised AMSTAR scores are
presented in Table 2, and the summarised ROBIS scores
are presented in Table 3. The justification statements for
ROBIS are presented in Table 6 in Appendix 4.
The 15 included reviews were published between 2003
and 2014 and originated from seven countries. The in-
cluded systematic reviews investigated the following therap-
ies: homoeopathy (n = 2), acupuncture (n = 7), chiropractic
(n = 1), herbal medicine (n = 1) and multiple CAMs (n = 4).
Results of each CAM therapy
Homoeopathy
Two individual reviews of homoeopathy for FM were iden-
tified [28, 29]. Four multiple CAM reviews [30–34] also
assessed homoeopathy. Perry et al. [28] included four RCTs
[35–38] (three of which were placebo-controlled [35–37]).
Their results suggested that homoeopathy was better than
the control interventions in alleviating the symptoms of
FM. However, none of the trials were without flaws. Using
the Jadad scale [39] to assess the quality of the studies, two
[35, 36] achieved a score of 3, one [37] achieved 4 and one
[38] just 2 out of a possible 5. Blinding issues, small sample
size, and lack of washout between crossover period were
mentioned as some of the problems identified.
The review and meta-analysis by Boehm et al. [29] identi-
fied the same four RCTs and one controlled clinical trial
(CCT) [40] (alongside ten case reports, three observational
studies). A meta-analysis of three RCTs [36–38] (n = 139)
revealed effects of homoeopathy on tender point count
(SMD= −0.42; 95% CI −0.78 to −0.05, P = 0.03, I2 = 0%),
compared to placebo. Tender points are pain points or
localised areas of tenderness around joints and are used to
diagnose FM [41]. Also, a meta-analysis of two RCTs and
one CCT [36, 38, 40] (n = 97) favoured homoeopathy in
pain intensity using a 100-mm VAS (SMD= −0.54: 95%
CI −0.97 to −0.10, P = 0.02; I2 = 42%), compared to pla-
cebo. As this latter meta-analysis also included the results
from the non-RCT, caution is needed in interpreting these
results. Homoeopathy had no effect on the McGill Pain
(MPQ) sensory scores (SMD= −0.08, 95% CI −0.51 to
0.34, P = 0.70, I2 = 0%) when pooling two RCTs [37, 38].
Using the Cochrane Risk of Bias tool [42], two trials had a
low risk of selection bias [37, 38], whilst the two rando-
mised crossover trials [35, 36] did not report methods of
randomization or allocation concealment. Only two trials
reported adequate blinding of participants and personnel
[36, 37], and all trials but one [40] reported adequate
blinding of outcome assessment. Risk of attrition, report-
ing or other bias was low in most trials. Thus far, the ef-
fectiveness of homoeopathy as a symptomatic treatment
for FM remains unproven.
Acupuncture
We identified seven systematic reviews [43–49] that
assessed acupuncture for FM alongside the four multiple
CAM reviews [30–34]. One of the earlier reviews was
conducted by Mayhew and Ernst [43] and included five
RCTs [50–54] (n = 316) of various forms of acupuncture
versus sham acupuncture (non-stimulation of acupunc-
ture point or stimulation at traditional needle location).
A meta-analysis was not performed, but the authors re-
ported that three of the five included studies [51–53]
found an effect of acupuncture. These effects were, how-
ever, mostly short-lived and, therefore, of debatable value
[43]. Of the remaining two trials that did not favour acu-
puncture, one [54] was considered well designed and of
good methodological quality using the Jadad scale [39].
Langhorst et al.’s [44] pooled analysis included seven
studies [50–52, 54–57] (n = 242) and found strong evi-
dence for the reduction of pain (SMD −0.25; 95% CI
−0.49 to −0.02; P = 0.04, I2 = 1%) at post-treatment com-
pared to sham or simulated acupuncture. The methodo-
logical quality was assessed by the 11-item van Tulder
score [58]). Sensitivity analyses demonstrated a significant
effect on pain at post-treatment in studies with high risk
of bias whereas the effect on pain at post-treatment in
studies of low risk of bias did not demonstrate an effect.
Martin-Sanchez et al. [45] found, from a pooled ana-
lysis of four studies [51, 52, 54, 55] (n = 257), a SMD be-
tween acupuncture and sham groups from baseline of
0.02 (95% CI −0.24 to 0.28) with regard to pain intensity,
but with wide confidence intervals which included the
null value. Between-study homogeneity was in evidence
(P = 0.41, I2 = 0%) for this comparison. No assessment of
quality or risk of bias was reported.
The meta-analyses conducted by Yang et al. (2014) [46]
were inaccurate as they used the control group twice in
the same analyses for two studies [53, 55]. Thus, we chose
not to report the results from the meta-analyses here.
Cao et al. (2013) [47] found that acupuncture had no
better effect than sham acupuncture with regard to pain
relief in people with FM, as shown in pooled analysis of
seven arms from five trials [52, 54, 55, 57, 59]. The change
in VAS score was reported as SMD −0.09 (95% CI −0.32
to 0.14, P = 0.44 I2 = 2%) and the VAS results at post-
treatment were SMD −0.22, (95% CI −0.51 to 0.07, P =
0.13, I2 = 26%). However, a pooled analysis of four trials
[60–63] showed acupuncture was better than
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antidepressants in reducing VAS pain scores: SMD −0.60
(95% CI −0.93 to −0.27, P = 0.0004, I2 = 22%). The small
sample size, scarcity of studies for each comparison, and
lack of an ideal sham weakens the level of evidence and its
clinical implications. The only analyses we have reported
here was that conducted on studies that compared acu-
puncture alone which did not incorporate mixed therapies
in the meta-analyses. Two out of the 16 trials were evalu-
ated as low risk of bias [55, 63], four [50, 54, 62, 63] were
rated as having unclear risk of bias, whilst the other ten
trials were evaluated as high risk of bias. Nine trials de-
scribed randomization [51, 54, 55, 59–62, 64, 65], and six
trials reported adequate allocation concealment [50, 51,
55, 59, 60, 64]. Three trials blinded both patients and out-
come assessors [51, 55, 63]. Five trials reported the num-
ber of dropouts [51, 57, 63–65], and none of these trials
used intention-to-treat analysis.
Deare et al.’s [48] Cochrane review identified eight
RCTs and one quasi-RCT [66]. This is one of the most
up-to-date systematic reviews on acupuncture. Pain se-
verity (VAS 100 mm) showed a reduction in pain for
those treated with real acupuncture compared with no
acupuncture at the end of treatment (mean difference
(MD) −22.40 points on a 100-point VAS scale; 95% CI
−40.98 to −3.82, P = 0.02, favouring acupuncture). This
was based on just one study [67]. Pain severity using
pooled analysis of six studies of the VAS, numerical rat-
ing scale (NRS), the Westhaven Yale Multi-dimensional
Pain Inventory (MPI) [68] and MPQ found no difference
between groups in reducing pain ((N = 286) SMD −0.14;
95% CI −0.53 to 0.24, P = 0.48, I2 = 54%). A short-term
benefit of acupuncture over antidepressants was found
in one study [66]; VAS = −17.3 on a 100-point scale; 95%
CI −24.1 to −10.5. All studies except one were at low risk
of selection bias; five were at risk of selective reporting
bias (favouring either treatment group); two were subject
to attrition bias (favouring acupuncture); three were sub-
ject to performance bias (favouring acupuncture) and one
to detection bias (favouring acupuncture). Using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) tool [42], they established there
was low- to moderate-level evidence that compared with
no treatment and standard therapy, acupuncture im-
proved pain and stiffness in people with FM. There was
moderate-level evidence that the effect of acupuncture
does not differ from sham acupuncture in reducing pain.
Electro-acupuncture was better than manual acupuncture
for pain and stiffness reduction, although the effects were
not maintained at 6 months follow-up.
Spinal manipulation (chiropractic/osteopathy)
There was just one review of chiropractic for FM consist-
ing of three RCTs [69–71] and one quasi-RCT [72] con-
ducted by Ernst in 2009 [73]. The reporting of the studies
in this review was generally poor; just two reported statis-
tical analysis of which neither found an effect of
Table 3 Tabular presentation for ROBIS results
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chiropractic treatment on pain. One quasi-experimental
study [72] reported a 34% pain reduction versus 26% re-
duction in control group using a 100-mm VAS (but no
further analysis was reported). However, both arms were
in combination with exercise and drugs. All the trials were
rated as low methodological quality according to the Jadad
scale [39] (either scoring 1 or 2 out of 5). The current trial
evidence is insufficient to conclude that chiropractic treat-
ment is an effective treatment for FM.
Baronowsky et al.’s (2009) [31] review of multiple
CAM therapies included one study of osteopathy [74]
which reported that the osteopathy group did better
than the control group in pain threshold in three tender
points; again, analysis was not reported.
Herbal medicine
There was just one review on herbal medicine for FM con-
ducted in 2013 by de Souza Nascimento [75]. This review re-
ported on eight studies of different types of herbal medicine.
One multiple CAM review also assessed herbal medicine
[32]. The results from both these reviews vary depending on
which herbal extract is used. No meta-analysis was conducted
due to heterogeneity of the interventions.
One study [76] using topical Capsicum (chilli pepper)
found an improvement in myalgia score, pressure pain
threshold, and Fibromyalgia Impact Questionnaire (FIQ).
Another study [77] found an improvement in sensitivity
and pain. Size of effects/P values were not reported in ei-
ther study. One RCT [78] found that nabilone was similar
to amitriptyline on pain scores and one [79] found a de-
crease in pain in nabilone group. Again, actual results were
not reported.
024-oil pain neutralizer, which contains camphor, eucalyp-
tus oil, aloe vera oil, peppermint oil, lemon and orange oil,
was investigated in two studies [80, 81]. Only one [80] re-
ported on pain and found an improvement in night pain rat-
ing and tender point count. Meta-050 (a combination of
reduced iso-alpha-acids from hops, rosemary, and oleanolic
acid) was also only assessed in one open study [82] and
found after 8 weeks, both pain and stiffness were moderately
improved. The methodological quality of all included trials
was evaluated by using Jadad scale [39] and two studies were
rated as good quality [76, 79], four studies moderate [77, 78,
80, 81] and two studies low [82, 83]. In addition, risk of bias
was assessed by the Cochrane Risk of Bias tool. Most studies
were low for section bias. Five of eight studies were double-
blind [77–81]; thus, these studies had a low risk of perform-
ance bias and low detection bias. No detailed evidence of se-
lective reporting was found in any of the eight studies.
Multiple CAM Reviews
Four systematic reviews [30–34] assessed several CAM
therapies within the same paper. We were only interested
in some of these therapies, so we have selected the CAMs
that were relevant to our review objectives and reported
them in the relevant sections above.
Adverse events
Poor reporting of adverse events (AEs) is a frequent criticism
of CAM research [84]. However, nine [30, 32, 43, 44, 46–49,
75] of the 15 reviews report on adverse events. A range of ad-
verse events were reported, depending on which CAM was
utilised. With regard to acupuncture, AEs were often either
exacerbations of existing symptoms or unpleasantness of the
intervention itself. Mild bruising, soreness, typically discom-
fort at site of needle and nausea were reported. In contrast,
palpitations, fainting, dry mouth, fatigue and constipation
were AEs associated with anti-depressant medication that
was used as treatment as usual in some groups. De Silva et al.
[32] found that in one homoeopathic study, allergic reactions
were reported. AEs were well reported in de Souza Nasci-
mento et al’s. [75] review of herbal remedies. Transient, burn-
ing and pricking, skin irritation, dizziness, nausea, dry mouth,
drowsiness, constipation and insomnia were some of the side
effects associated with herbal medicines.
Quality of included reviews
Results of AMSTAR A summary of the AMSTAR results
can be found in Table 2. Nine reviews reported using two
data extractors and achieving study consensus. Just one re-
view did not report conducting a risk of bias assessment
[45], and two [29, 45] did not apply the quality assessment
appropriately in light of the findings. Only one included an
‘excluded studies’ table [48]. Seven reviews [28, 29, 44, 45,
47–49] included detailed characteristics of the included
studies; the majority had some form of table, but not every
review reported on participant details. Details on the inter-
vention and outcomes were generally better reported in
most reviews. The methods used to combine the studies
were reported and appropriate in 11 reviews. Four assessed
likelihood of publication bias (through funnel plots) [44, 46,
48, 53]. None of the reviews stated conflict of interest of
the individual studies. Overall, five reviews scored 6 or
above on the AMSTAR scale [28, 44, 46–48]. The inter-
rater agreement was good (Ƙ = 0.70), with 83.6% agreement
between the two raters (RP, VL).
Results of ROBIS The ROBIS tool is divided into four
domains (see Table 3 for summary of results and Appen-
dix 1 for full results). With regard to domain 1, which
assessed any concerns regarding specification of study
eligibility criteria, nine reviews [28, 33, 34, 43–48, 75]
achieved a low risk of bias rating overall. Domain 3
assessed concerns regarding methods used to collect
data and appraise studies, and seven studies achieved a
low risk of bias rating [28, 29, 33, 34, 44, 47, 48, 75].
With regard to domain 4, which assessed concerns
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regarding the synthesis and findings, there was more
variation in the scores; six were assessed as high [29, 33,
34, 45, 46, 49, 75], four unclear [28, 30, 32, 73] and five
scored low [31, 43, 44, 47, 48]. The reviews that did not
conduct a meta-analysis were hard to assess using
ROBIS. The final section provides a rating for the overall
risk of bias of the reviews; seven achieved a low rating
[28, 32, 43, 44, 47, 48, 75], six a high rating [29, 30, 33,
34, 45, 46, 49] and two were rated as unclear [31, 73].
The inter-rater agreement was fair (Ƙ = 0.32), with 60.0%
agreement between the two raters (RP, VL).
Discussion
Summary of the main results
Homoeopathy
Two individual reviews and four multiple CAM reviews
assessed homoeopathy for FM. The most recent review
[29] included the same RCTs as Perry et al. [28] but also
included 13 observational studies. This achieved 5/11 on
Amstar and was considered high risk of bias by ROBIS.
Perry et al. [28] was a more robust review with a low risk
of bias rating by ROBIS and scoring 6 (high quality) on
AMSTAR. Although there was some positive effects dem-
onstrated, more research is needed before homoeopathy
can be considered a viable alternative treatment for FM.
Acupuncture
From the seven acupuncture reviews and four multiple
CAM reviews, the most robust evidence regarding acu-
puncture comes from Deare et al.’s [48] Cochrane re-
view. This achieved a positive response on 10/11 on the
AMSTAR components and was judged to be of low risk
of bias on each of the five ROBIS domains. They con-
cluded that there was low-quality evidence that acu-
puncture improves pain compared to no treatment or
standard treatment, but good quality evidence that it is
no better than sham acupuncture. This is an interesting
and unexpected result as it implies that acupuncture is
equivalent to placebo but more effective than standard
care (antidepressants). However, the sham conditions
varied from sham needling to acupuncture in a non-
acupuncture place, which might indicate there were
blinding issues in some of these sham groups. Alterna-
tively, it could indicate there is a genuine placebo re-
sponse to sham acupuncture. As this is one of the most
recent and robust reviews, its conclusions carry more
weight than the other reviews on acupuncture.
Spinal manipulation
One review of chiropractic [73] was identified and scored 3/
11 on AMSTAR and assessed as high risk of bias on ROBIS.
There were several problems with the individual RCTs; thus,
the results were inconclusive. One multiple CAM review
[31] assessed osteopathy and indicated the results favour
osteopathy over standard care alone. However, this review
was rated as unclear on ROBIS and scored 3 on AMSTAR.
Herbal medicine
The one herbal medicine review [75] and one multiple
CAM review [32] both indicated some evidence for top-
ical Capsicum. 024-oil and nabilone also reported posi-
tive results for pain. However, as nabilone is made up of
cannabinoid extract, it may not be considered a pre-
ferred treatment option for some people with FM. de
Souza Nascimento et al. [75] only scored 4/11 on
AMSTAR but achieved a low risk of bias score when
using ROBIS which indicates different interpretations/
assessments of quality when using the two tools.
Overall completeness and applicability of evidence
With regard to the eight CAMs we were interested in,
our overview is in agreement with Lauche et al.’s [24]
work which suggested that acupuncture had the best evi-
dence of effectiveness for FM, conflicting results for
chiropractic and inconclusive results for homoeopathy
and phytotherapy (herbal medicine). In addition, some
reviews that we identified were missing from Lauche’s
overview [29, 46, 47, 49]. It is unclear from their inclu-
sion/exclusion criteria why these four reviews would
have been excluded. Thus, our overview provides a more
up-to-date overview of the selected CAMs.
Our overview also drew similar conclusions to Terry et al.’s
[1]. They also found some evidence of beneficial effects aris-
ing from both acupuncture and homoeopathy for the treat-
ment of FM symptoms, whilst no evidence for therapeutic
effects from chiropractic interventions was found.
Quality of the evidence
To date, AMSTAR is one of the main scales for assessing
quality of a systematic review. It is quick and easy to
complete, and there was good inter-rater reliability (kappa
= 0.70, agreement 83.6%). In general, there was consistency
between ROBIS and AMSTAR. Five reviews [28, 44, 46–
48] achieved a high overall rating (scores >6) with the
AMSTAR scale (although AMSTAR is not designed to have
a final score). These five reviews also all scored low risk of
bias on ROBIS. There were discrepancies on rating for
three reviews; Mayhew and Ernst [43] achieved a low risk
of bias but scored just 3 on AMSTAR, Yang et al. [46]
achieved a high risk of bias but scored 6 on AMSTAR and
de Souza Nascimento et al. [75] achieved a low risk of bias
score on ROBIS but scored 4 on AMSTAR.
If a meta-analysis was included, this made rating domain
4 of the ROBIS tool easier to complete. Narrative syntheses
were much harder to rate on this particular domain. There
is little information in the ROBIS guidance document on
how to score the signalling questions where no quantitative
synthesis has been done or where the small number
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of studies included in the quantitative synthesis does
not permit exploration of the data with regard to het-
erogeneity, robustness of the finding and quality. De
Silva et al. [32] was an interesting review. Despite
scoring high or unclear for domains 1–4 they still
achieved a low score overall; this was because they
did not overemphasise their findings and were able to
critique their shortcomings of the review process.
This highlights one of the strengths of ROBIS.
Potential bias in the overview process
One author evaluated their own work [RP: 28] and one of
the developers of ROBIS (PD) was involved in the apply-
ing ROBIS to assess the included reviews. Another of the
developers of ROBIS (RC) was involved in the write up of
the report. Although the search strategy was comprehen-
sive, it is possible that some relevant reviews may not have
been identified. In addition, a limitation of the overview is
that several of the included reviews would be considered
out of date (more than 5.5 years) [85]. Some reviews were
excluded, due to language restrictions we imposed. This
was due to requiring a trained person in the ROBIS tool
to complete the assessment. This meant two potential re-
views were excluded due to language [86, 87] (see Table 4
in Appendix 2). Despite these issues we believe the sys-
tematic approach to this overview minimises bias. Diffi-
culties in using ROBIS may have led to errors in
interpretation; lower inter-rater reliability was achieved
than when using AMSTAR. In addition, CAM papers tend
to be published in lower impact journals and often re-
stricted by word count. Earlier reviews did not tend to
score so highly on either tool probably because reporting
criteria have changed over time.
Conclusions
Authors’ conclusions
Implications for CAM practice
Of all the CAM interventions included, acupuncture re-
ceived the most positive assessment in terms of effective-
ness. This was the conclusion from the most recent
Cochrane review [48]. This review was rated as good qual-
ity using AMSTAR and low risk of bias using ROBIS. Fur-
ther well-conducted trials on herbal extracts such as
Capsicum, nabilone and 0il-24 would also be beneficial.
Implications for future research
There is clearly a need for larger and more methodo-
logically sound RCTs to be conducted on the effective-
ness of some CAM therapies for FM. Acupuncture, in
particular, had several trials investigating its efficacy for
FM. Future trials could adopt the following RCT design:
to compare drug plus sham acupuncture versus placebo
drug plus CAM intervention. This would enable the
sham condition to be tested properly.
Both reviews assessing herbal medicine [32, 75] indicated
some evidence for topical Capsicum but more research is
needed. More research is also needed before homoeopathy
can be considered a viable alternative treatment for FM.
Overall conclusions
Overall, no firm conclusions were drawn for either spinal
manipulation or homoeopathy for FM. There is limited
evidence for topical Capsicum to alleviate symptoms of
FM, but more research is needed. There is some evidence
to support the effectiveness of acupuncture for FM, and
further high-quality trials are needed to investigate its
benefits, harms and mechanisms of action, compared with
no or standard treatment before this can be considered a
viable alternative treatment for FM.
Appendix 1
Description of CAM therapies
Acupuncture is the insertion of the tips of needles into
the skin at specific points for the purpose of treating
various disorders by stimulating nerve impulses. Origin-
ally Chinese, this method of treatment is practised in
many parts of the world [88]. It aims to restore balance
to enable the chi to free flow around the meridians. Each
meridian is associated with a particular organ [89].
Western medical acupuncture has evolved from these
ideas and is more about stimulating the nervous system
(http://www.nhs.uk/Conditions/hypnotherapy/Pages/
Introduction.aspx). Acupuncture is one of the more
established CAM therapies within primary care, and it is
an important CAM to review [21].
Hypnotherapy is a form of induced sleep which was
originally used to diminish pain during surgery but soon
became redundant with the advent of anaesthesia [90]. It
is used to create subconscious change in a patient in the
form of new responses, thoughts, attitudes, behaviours
or feelings. It is often used in treating anxiety states,
stopping addictions and reducing pain [91].
Homoeopathy is based on the principle of like cures
like [92]. The remedies are prepared by dilution and
energised through succession. Several aspects of the
treatment (e.g. long, empathetic consultation and a high
degree of individualising the remedies) might make it
particularly attractive to patients with FM [93].
Osteopathy is a way of detecting, treating and preventing
health problems by moving, stretching and massaging a
person’s muscles and joints (http://www.nhs.uk/conditions/
Osteopathy/Pages/Introduction.aspx).
Chiropractors uses less leverage and quicker manipula-
tions than osteopathy, also uses soft tissue massage, exer-
cise, corsets, splints and supports (http://www.nhs.uk/
conditions/chiropractic/pages/introduction.aspx). The
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mechanical technique of either form of spinal manipulation
might make it less attractive to FM sufferers as the pain
tends to be throughout the body and manipulation may
worsen this pain.
Herbal medicine is the use of plant extracts/mate-
rials for food medicine and health promotion. Medi-
cinal plants have multiple actions; some of which are
toxic. As humans, we are raised in a diet of herbs
and plants so the suggestion is that we are better
adapted to them than synthetic drugs. The plants are
used in a variety of ways: dried fresh, infusion or de-
coctions [88].
Reflexology is a specialist foot massage which con-
centrates on specific zones on your foot relating them
to major organ systems within the body. Blocks or
disturbances within the connecting energy system
allow for disease to build up, and these channels need
unblocking [94].
Aromatherapy is the use of essential oil or aromatic
essences massage into the skin, inhaled or occasionally
ingested. The oils are extracted from the petals, leaves,
stem or bark of the plant [95].
Appendix 2
Appendix 3
MEDLINE search terms
1. systematic review.ti,ab.
2. meta-analysis.pt.
3. meta-analysis.ti,ab.
4. systematic literature review.ti,ab.
5. review.pt.
6. evidence synthesis.ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Fibromyalgia/
9. (chronic adj widespread adj pain).ti,ab.
10. fibrositis.ti,ab.
11. fibromyal*.ti,ab.
12. fibromylagia.ti,ab.
13. 8 or 9 or 10 or 11 or 12
14. homeopathy.ti,ab.
15. homeopathic.ti,ab.
16. homeop*.ti,ab.
17. homoeopathy.ti,ab.
18. homoeopath*.ti,ab.
19. homoop*.ti,ab.
20. exp Homeopathy/
21. 14 or 15 or 16 or 17 or 18 or 19 or 20
22. acupuncture therapy.ti,ab.
23. electroacupuncture.ti,ab.
24. acupuncture*.ti,ab.
25. acupoint.ti,ab.
26. meridian.ti,ab.
27. moxibustion.ti,ab.
28. exp acupuncture/
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. (spin* adj3 manipulation*).ti,ab.
31. (osteopath* adj manipul*).ti,ab.
32. (high adj3 velocit* thrust).ti,ab.
33. (spin* adj3 adjust*).ti,ab.
34. (sham adj3 manipulation*).ti,ab.
35. exp Manipulation, Chiropractic/
36. exp Manipulation, Spinal/
37. exp Manipulation, Osteopathic/
38. chiropract*.ti,ab.
39. osteopath*.ti,ab.
40. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
or 38 or 39
41. exp Hypnosis/
42. (hypno* or autogenic* or mesmer* or guided
ima*).ti,ab.
43. 41 or 42
44. reflexolog*.ti,ab.
45. reflexolog* treatment*.ti,ab.
46. foot massage*.ti,ab.
47. zone therap*.ti,ab.
48. 44 or 45 or 46 or 47
49. (herbal* or medical herbal* or TCM).ti,ab.
50. exp Drugs, Chinese Herbal/
51. exp Phytotherapy/
52. 49 or 50 or 51
57. 13 or 21 or 29 or 40 or 43 or 48 or 52
58. 7 and 13 and 57
Table 4 Excluded reviews
Author (date) Reason for exclusion
Berman BM [105] Not a systematic review
Schneider M [106] Consensus report
Sim J [107] Multiple CAM review with
just one relevant study included
Langhorst J [86] German language (needed translation)
Lauche [87] German language (needed translation)
Hardy-Pickering [108] Overview of systematic reviews
(conducted in 2007—so considered
out of date)
Table 5 Table of reviews in progress
Boyd A
[109]
Herbal medicinal products or preparations for neuropathic
pain and fibromyalgia PROTOCOL (Cochrane review) At
August 2016, this protocol was withdrawn due to the full
review not meeting the quality standards and
expectations of Cochrane and the PaPaS review group.
Jones GT
[110]
Published as part of a report: Arthritis Research UK—A
report on Complementary and alternative therapies.
‘Practitioner-based CAM for the treatment of rheumatoid
arthritis, osteoarthritis, FM and low back pain.’
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Appendix 4
Table 6 Summary of the ROBIS domains
Review 1. Study eligibility criteria 2. Identification and
selection of studies
3. Data collection and
study appraisal
4. Synthesis and findings 5. Risk of bias in the
review
Homeopathy
Perry (2010) Low: There was no
mention of a review
protocol but did
mention that the
inclusion/exclusion
criteria were pre-defined.
Some additional search-
ing took place; reference
lists and other reviews
were hand-searched.
Low: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports. The
review was restricted to
published studies. Two
reviewers looked at full
texts, but this was not
specifically stated for
abstract screening.
Low: Two reviewers
independently
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Jadad score [39]) with
allocation concealment
being assessed in
addition.
Some study
characteristics were
extracted (main table),
but information was
missing on participants.
Appropriate results
appear to have been
collected although this is
not completely clear.
Unclear: There was
heterogeneity; thus, no
meta-analysis was per-
formed. Each study was
discussed and evaluated
in detail, and a sufficient
synthesis occurred. The
results of the risk of bias
assessment were re-
ported in full. This narra-
tive review assesses the
results appropriately and
the conclusion reflects
this.
Low: The main concerns
arising from this were
the potential for missed
studies through not
includ unpublished
papers. The conclusions
seem fair in relation to
these considerations.
Boehm
(2014)
High: There was no
mention of a review
protocol or pre-
specification of review
objective. There were
some concerns regarding
the specification of the
eligibility criteria with re-
gard to diagnosis of
fibromyalgia. No specific
list of outcomes stated.
Low: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports.
Limited details on the
search strategy. The term
‘homeopathy’ was used
which would not pick up
‘homeopathic’.
Low: Two reviewers
independently
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Cochrane risk of bias
[42]). Appropriate study
characteristics were
extracted, and
appropriate results
appear to have been
collected.
High: One Fisher study
(1986) was not included
in the synthesis, but it
unclear why it was
excluded. Combining
RCTs with non-RCTs will
introduce bias.
High: The discussion is
mostly cautious although
the final sentence is a bit
over-confident.
Some attention given to
inclusion of different
study designs and the
ambiguous definition of
homeopathic remedy.
Acupuncture
Mayhew
(2007)
Low: There was no
mention of a review
protocol or pre-
specification of review
objective. There was
some concern regarding
the specification of the
eligibility criteria with re-
gard to outcomes as no
outcomes were
mentioned.
High: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports.
Limited details were
available for the search
strategy; the full search
was not reported.
Methods used to screen
references and select
studies for inclusion were
not reported.
High: Two reviewers
independently
performed data
extraction. It was unclear
if the two assessed risk of
bias. Risk of bias was
assessed using
appropriate criteria
(Jadad score [39])
although allocation
concealment is not
assessed. There was
some reporting of means
and percentage
differences between
groups but not for every
study. They also failed to
define outcome at the
start.
Low: There was limited
result information given
and as there was no
protocol; we cannot
check outcomes that
were intended to be
assessed. This is not
really a synthesis, more
like a list of finings.
Low: Although some of
the domains had issues,
the conclusion does take
into account some of the
weaknesses of the
studies and does not
overemphasise any
positive findings.
Daya (2007) High: There was no
mention of a review
protocol or pre-
specification of review
objective. Lack of detail
on eligibility criteria and
High: Although the
search included
appropriate databases to
identify published
studies, searches did not
include trial registries or
conference reports.
High: One reviewer
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Stricta [104]).
High: The results of the
individual studies are
reported without any real
attempt at a synthesis.
The quality scale also
includes other items
which is likely to affect
High: The conclusions
seem appropriate for the
limitations of the
evidence. Main concerns
are the potential for
missing studies from the
limited search and
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Table 6 Summary of the ROBIS domains (Continued)
limited to English
language.
Limited details were
available for the search
strategy (no mention of
MeSH headings). It
appears that the review
was restricted to
published studies.
Methods used to screen
references and select
studies for inclusion were
not clearly reported and
appeared to be done by
just the author, so no
cross-checking.
Appropriate study
characteristics were
extracted (main table)
but only P values appear
to have been extracted.
the overall score.
Conflicting results
between the highest
quality studies suggests
the findings were not
robust.
mainly due to a single
person conducting the
review with no cross-
checking.
Langhorst
(2010)
Low: There was no
mention of a review
protocol or pre-
specification of review
objective. However, there
were very detailed eligi-
bility criteria. The search
was restricted to fully
published studies. The
type of acupuncture was
restricted to ‘verum’ acu-
puncture (inserting nee-
dles). Acupressure, TENS,
and infrared light were
excluded, which are ap-
propriate exclusions.
Low: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports.
Reference lists, other
systematic reviews, and
evidence-based guide-
lines were also searched.
The search looks reason-
able and is transparent.
Methods used to screen
references and select
studies for inclusion were
clearly reported.
Low: Two reviewers
extracted data, but it
does not state directly in
the text if two reviewers
independently
performed risk of bias
assessment (van Tulder
score [58]). Risk of bias
was assessed using
appropriate criteria.
Appropriate study
characteristics were
extracted (main table).
Low: There is a slight
error in reporting of
results in text and in
forest plots. Publication
bias could not be
assessed due to low
number of studies.
Sensitivity analysis looked
at those with low risk of
bias did not show an
effect in the meta-
analysis.
Low: Main concerns
arising from this review
were the potential for
publication bias though
only including published
studies. It did not clearly
state whether two
people assessed risk of
bias. However, the
analysis and sensitivity
analysis were appropriate
and thorough and
helped the authors draw
more conservative and
appropriate conclusion.
Martin-
Sanchez
(2009)
Low: There was no
mention of a review
protocol or pre-
specification of review
objective. Inclusion cri-
teria were brief but there
did not appear to have
any restrictions.
High: Although the
search included
appropriate databases to
identify published
studies, searches did not
include trial registries or
conference reports.
Limited details were
available for the search
strategy. No MeSH terms
were mentioned, and full
search was not reported.
They did not search any
CAM databases. Limited
number of references
identified. There was no
information on
restrictions e.g. date,
publication format,
language. Methods used
to screen references and
select studies for
inclusion were not clearly
reported.
High: There was
insufficient reporting on
all aspects of data
collection, risk of bias
assessment and results.
High: It was unclear why
studies were not
included in the meta-
analysis. The first meta-
analysis consisted of 4 of
6 studies. Heterogeneity
was discussed briefly.
There was no quality as-
sessment, so no insight
into methodological
quality or risk of bias. No
sensitivity analysis.
High: None of the
limitations identified
were considered in the
discussion. Think it is
highly likely that
reviewers have missed
studies. No consideration
of study quality, which is
a key component of
systematic reviews.
Deare
(2013)
Low: Cochrane reviews
are required to have a
protocol which is peer
assessed before the
review can commence.
No restrictions on
language and publication
type. There were
restrictions in studies that
did not provide
adequate details of
control group.
Conference abstracts
Low: There were no
major concerns with this
section. It appears just
one reviewer did the
screening of titles and
abstracts though.
Low: No concerns with
this section. Two
reviewers independently
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Cochrane [42]).
Appropriate study
characteristics were
extracted (main table),
and appropriate results
Low: No major concerns;
however, one thing to
highlight is concerning
robustness of the
findings. This judgment
depends on the
comparison:
Acupuncture V no
acupuncture
(just 1 study)
Acupuncture V placebo/
sham (robust findings)
Low: The conclusion was
appropriate and
addressed the concerns
raised.
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appear to be excluded
(see flow diagram).
appear to have been
collected.
Cao (2013) Low: There was no
mention of a review
protocol or pre-
specification of review
objective.
However, outcomes were
not clearly specified and
did not appear to
constitute an objective
pre-specified list.
High: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports.
The search strategy
appeared
comprehensive, but it
was unclear if both
MeSH and text word
used. It appears that the
review was restricted to
published studies
although this was not
completely clear.
Methods used to screen
references and select
studies for inclusion were
clearly reported.
Low: Two reviewers
independently
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Cochrane ROB [42]).
Appropriate study
characteristics were
extracted (main table),
and appropriate results
appear to have been
collected although this is
not completely clear.
Low: Unclear if MA
included all suitable
papers. Lack of guidance
on ROBIS tool about how
to appropriately consider
robustness of quality on
results when there is
insufficient numbers of
studies.
Low: The conclusion
seemed to address all
the concerns raised in
the other domains.
Yang (2014) Low: There was no
mention of a protocol,
but there was detailed
pre-specification of re-
view objectives. Over all,
there were limited con-
cerns with this domain
but the texts were re-
stricted to Chinese and
English which should be
ok for an acupuncture
review.
Low: Although the
search included
appropriate databases to
identify published
studies, searches did not
include trial registries or
conference abstracts.
Methods used to screen
and select studies for
inclusion were clearly
reported. The language
restriction has been dealt
with in domain 1.
High: Risk of bias was
assessed using Cochrane
criteria; however, both
Harris (2005) and Guo
(2005) have been
assessed twice and have
very different risk of bias
scores despite being the
same study. This is
confusing and questions
whether errors have
been made in the
assessment.
High: In the meta-
analysis, the reviewers
could have synthesised
the VAS and NRS in the
same forest plot. Again,
there is an issue of Harris
and Guo appearing twice
in the plots even though
they are the same study
(with the same control
arm). Results are not ro-
bust as there are insuffi-
cient studies to assess
robustness.
High: ‘Despite the
methodological
limitations the superiority
of acupuncture in the
treatment of FMD
cannot be denied’ is an
overstatement. The flaws
in the assessment of risk
of bias and the
untrustworthy results
from the meta-analysis
make this review of high
risk of bias.
Chiropractic
Ernst (2009) High: There was no
mention of a review
protocol but did
mention that the
inclusion/exclusion
criteria were pre-defined.
No mention of patients
with a formal diagnosis
of fibromyalgia.
Unclear: Although the
search included
appropriate databases to
identify published
studies, searches did not
included trial registries or
conference reports.
Departmental files were
searched (which could
be a biased selection)
and hand-searching took
place. The full search
strategy was not
provided.
Methods used to screen
references and select
studies for inclusion were
not clearly reported. It
was not reported how
many reviewers screened
titles and abstracts.
High: Two reviewers
independently
performed data
extraction and risk of bias
assessment. Risk of bias
was assessed using
appropriate criteria
(Jadad score [39])
although allocation
concealment was not
assessed.
Some study
characteristics were
extracted (main table),
but information was
missing on participants.
Appropriate results
(when available) appear
to have been collected
although this is not
completely clear.
Unclear: The results of
the risk of bias
assessment were
reported in full; however,
allocation concealment
was not assessed. This
narrative review assesses
the results available;
however, no numerical
results given.
Heterogeneity was not
formally assessed. The
results from Wise and
Walsh were not reported
in the primary study;
thus, a possible source of
bias as their results could
affect the overall
conclusions.
Unclear: The conclusions
are inconclusive which is
reasonable based on the
evidence available. The
possibility of missing
studies is discussed. The
studies are rated low
quality so item on
allocation concealment is
unlikely to have changed
this (Jadad scale).
Herbal medicine
de Souza
Nascimento
(2013)
Low: The review did not
refer to a protocol;
however, the inclusion/
exclusion criteria were
pre-defined. The review
was restricted to English
Low: The search included
appropriate databases to
identify published
studies. Reference lists
were hand-searched. The
search looks reasonable
Low: It states in the text
that two reviewers
independently
performed risk of bias
assessment. Risk of bias
was assessed using
High: No protocol
provided
Heterogeneity not
discussed. It was unclear
why certain studies could
not be combined.
Low: Main concerns
arising from this were
the potential for
publication bias through
only including published
studies and restricting to
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language papers only.
Not much grey literature
searching took place.
and is transparent, al-
though CAM-specific da-
tabases were not
searched.
It is unclear whether
unpublished papers
would be identified. It
appears that the review
was restricted to
published studies. Trial
registries were not
searched.
Methods used to screen
references and select
studies for inclusion were
not clearly reported.
appropriate criteria (both
Jadad and Cochane).
Insufficient study
characteristics were
extracted, and there was
not enough information
about the actual results
obtained—just ‘a
significant difference was
found.’
No actual data provided,
just a summary of the
result. Unclear which
results were used to
come to these
conclusions. A pilot study
was mentioned (Triaste)
but no further
information as to why
this was excluded.
Narrative synthesis of
results mentioned the
direction of effect but no
information about the
size of the effect.
English language only.
There was a tendency to
emphasise the positive
findings. They made no
mention of the small
number of studies or the
risk of bias in those
studies when
interpreting the results.
Multiple CAM
Holdcroft
(2003)
High: There was no
mention of a review
protocol and ambiguous
eligibility criteria. There
were no fibromyalgia
criteria or any outcomes
listed. One restriction
was to only include
those studies judged as
good quality of
reporting.
High: Although the
search included
appropriate databases to
identify published
studies; searches did not
included trial registries or
conference reports.
Search strategy was not
available and they have
not put the term for
homeopathy in
(although they do
retrieve one study on
homeopathy). There are
odd search dates for
Embase and CINAHL
which restrict the search.
There is no information
about study selection.
High: There was no
information about
participants or how
outcomes were
measured. Little
information about dose
and nothing on study
design. One reviewer
performed data
extraction and quality
assessment. The
CONSORT checklist was
used as a quality
assessment tool which is
inappropriate. No results
are displayed in the table
or results section just a
statement ‘differed
significantly’.
Unclear: No numerical
synthesis due to
heterogeneity; there was
no flow diagram and no
list of included
outcomes, so it is unclear
whether results of
studies were not
included that should
have been (possibility of
‘cherry-picking’ the
results). Study design and
quality is considered in
the narrative; however,
the CONSORT checklist is
an inappropriate scale to
assess quality.
High: The conclusion
was suitably cautious but
no mention of limitations
identified in domains 1-3.
Baronowsky
(2009)
High: There was no
mention of a review
protocol or pre-
specification of review
objectives. No mention
of comparators or out-
come of interest. Articles
were restricted to English
and German languages
only which may have
missed some papers (par-
ticularly Chinese). Nutri-
tional, Herbal medicine
and hormonal supple-
ments were excluded
from the review.
High: Although the
search included
appropriate databases to
identify published
papers, and the terms
appears to cover all the
CAM therapies that were
needed (although no
MeSH terms listed), it
appears this restricted to
published papers. Studies
are likely to have been
missed due to not
searching beyond
electronic databases.
Details of the screening
process were not clearly
reported.
Unclear: Quite a few
items on the quality
assessment checklist are
not about quality so this
will affect the score. Also,
it is not clear how many
people assessed quality.
Limited information
reported on participants.
Insufficient results are
presented, and actual
results (means, SDs) were
not reported. P values
were reported
occasionally within a
statement mentioning
significance.
Low: There was
insufficient reporting of
outcomes evaluated and
the numerical results.
This is particularly an
issue when there is no
meta-analysis available.
Unclear: Overall, the
results show a positive
trend in favour of
acupuncture. Which
might be overstating the
findings a bit. The
possibility of missing
studies is discussed
however.
De Silva
(2010)
High: There was no
mention of a review
protocol and a limited
pre-specification of re-
view objective. Inclusion
was restricted to studies
a complementary medi-
cine substance in the UK
which restricts this
High: Although the
search included
appropriate databases to
identify published
studies, limited details
were available for the
search strategy. The RCT
filter was very basic and
likely to miss some trials.
High: Not all data was
provided, e.g. results of
some studies were not
reported. Some P values
reported in text. No
information in the
methods section about
results data to be
collected. One reviewer
Unclear: They seemed to
have reported the same
number of results as
number of studies
although not all P values
given. No pre-defined
analysis. No description
of outcomes of interest
given in the paper so
Low: Rationale for risk:
the small number of
studies, methodological
limitations and limiting
the search to English
language only. Use of
the Jadad scale was
another issue. However,
the conclusion does say
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